KR100633375B1 - 피라지노(아자)인돌 유도체들 - Google Patents

피라지노(아자)인돌 유도체들 Download PDF

Info

Publication number
KR100633375B1
KR100633375B1 KR1020017009583A KR20017009583A KR100633375B1 KR 100633375 B1 KR100633375 B1 KR 100633375B1 KR 1020017009583 A KR1020017009583 A KR 1020017009583A KR 20017009583 A KR20017009583 A KR 20017009583A KR 100633375 B1 KR100633375 B1 KR 100633375B1
Authority
KR
South Korea
Prior art keywords
compound
indole
hydrogen
chloro
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017009583A
Other languages
English (en)
Korean (ko)
Other versions
KR20010101873A (ko
Inventor
데이비드 레지날드 아담스
존 마크. 벤틀리
제임스. 데이비드슨
매튜 알렉산더 제임스 둔크톤
리차드 휴 필립. 포터
Original Assignee
베르날리스 리서치 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르날리스 리서치 리미티드 filed Critical 베르날리스 리서치 리미티드
Publication of KR20010101873A publication Critical patent/KR20010101873A/ko
Application granted granted Critical
Publication of KR100633375B1 publication Critical patent/KR100633375B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
KR1020017009583A 1999-01-29 2000-01-28 피라지노(아자)인돌 유도체들 Expired - Fee Related KR100633375B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9902047.1A GB9902047D0 (en) 1999-01-29 1999-01-29 Chemical compounds XI
GB9902047.1 1999-01-29

Publications (2)

Publication Number Publication Date
KR20010101873A KR20010101873A (ko) 2001-11-15
KR100633375B1 true KR100633375B1 (ko) 2006-10-16

Family

ID=10846774

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017009583A Expired - Fee Related KR100633375B1 (ko) 1999-01-29 2000-01-28 피라지노(아자)인돌 유도체들

Country Status (18)

Country Link
US (4) US6800627B1 (https=)
EP (1) EP1147110B1 (https=)
JP (1) JP2002535408A (https=)
KR (1) KR100633375B1 (https=)
CN (2) CN1289499C (https=)
AT (1) ATE239731T1 (https=)
AU (1) AU758685B2 (https=)
BR (1) BR0008979A (https=)
CA (1) CA2359034A1 (https=)
DE (1) DE60002554T2 (https=)
DK (1) DK1147110T3 (https=)
ES (1) ES2199132T3 (https=)
GB (1) GB9902047D0 (https=)
MX (1) MXPA01007643A (https=)
PT (1) PT1147110E (https=)
TR (1) TR200102161T2 (https=)
WO (1) WO2000044753A1 (https=)
ZA (1) ZA200106202B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4180365B2 (ja) 2000-07-31 2008-11-12 エフ．ホフマン−ラ ロシュ アーゲー ピペラジン誘導体
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
NZ525699A (en) 2000-11-20 2005-03-24 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor
EP1343768A1 (en) * 2000-12-20 2003-09-17 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
AU2002259312B2 (en) 2001-06-01 2007-01-04 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
EP1392658A4 (en) 2001-06-01 2004-10-13 Alcon Inc NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE IN THE TREATMENT OF GLAUCOMES
EP1392292B1 (en) 2001-06-01 2006-03-01 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
JP4460450B2 (ja) 2002-06-19 2010-05-12 ビオヴィトルム・アクチボラゲット（プブリクト） 新規化合物、その使用および製造法
CA2506204A1 (en) 2002-12-13 2004-07-01 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
NZ543482A (en) * 2003-05-21 2009-02-28 Prosidion Ltd Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2005058911A2 (en) 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
CN101171252B (zh) * 2005-05-03 2011-06-01 霍夫曼-拉罗奇有限公司 作为5-ht2配体的四环氮杂吡嗪并二氢吲哚类化合物
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
ES2344077T3 (es) 2005-12-16 2010-08-17 F.Hoffmann-La Roche Ag Derivados de pirrolo(2,3-b)piridina como moduladores del receptor h3.
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
EP2254886B1 (en) 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
MX363662B (es) * 2012-10-08 2019-03-27 Centro De Investig Y De Estudios Avanzados Del I P N Star Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2.
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JP6217561B2 (ja) * 2014-08-21 2017-10-25 信越化学工業株式会社 新規オニウム塩化合物及びレジスト組成物並びにパターン形成方法
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
WO2021086038A1 (ko) * 2019-10-31 2021-05-06 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792724A (fr) * 1971-12-16 1973-06-14 Merck Patent Gmbh Derives de pyrazinoindole et leur procede de preparation
EP0572863A1 (de) * 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
GB9819019D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819032D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds IV
GB9918962D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii

Also Published As

Publication number Publication date
US20040039200A1 (en) 2004-02-26
GB9902047D0 (en) 1999-03-17
TR200102161T2 (tr) 2002-05-21
EP1147110B1 (en) 2003-05-07
ES2199132T3 (es) 2004-02-16
MXPA01007643A (es) 2003-06-24
KR20010101873A (ko) 2001-11-15
WO2000044753A1 (en) 2000-08-03
ATE239731T1 (de) 2003-05-15
PT1147110E (pt) 2003-09-30
US20060160816A1 (en) 2006-07-20
ZA200106202B (en) 2002-07-29
JP2002535408A (ja) 2002-10-22
DE60002554T2 (de) 2004-03-25
DK1147110T3 (da) 2003-09-01
BR0008979A (pt) 2002-02-05
CN1289499C (zh) 2006-12-13
US20040092525A1 (en) 2004-05-13
US7145009B2 (en) 2006-12-05
US6800627B1 (en) 2004-10-05
AU2119600A (en) 2000-08-18
CN1337963A (zh) 2002-02-27
CA2359034A1 (en) 2000-08-03
AU758685B2 (en) 2003-03-27
CN100418968C (zh) 2008-09-17
DE60002554D1 (de) 2003-06-12
EP1147110A1 (en) 2001-10-24
CN1837207A (zh) 2006-09-27

Similar Documents

Publication Publication Date Title
KR100633375B1 (ko) 피라지노(아자)인돌 유도체들
KR100740172B1 (ko) 인돌 유도체들, 이들의 제조 공정, 이들을 함유한약제학적 조성물들 및 그 조성물들의 의약적 적용
JP4047723B2 (ja) インドリン誘導体、および５−ｈｔ２受容体リガンドとしてのその使用
KR100539139B1 (ko) 피페라진 유도체
US7173056B2 (en) Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
CN102015711B (zh) 用于治疗寄生虫病的螺-吲哚衍生物
JP2004517852A (ja) インドール誘導体および５−ｈｔ２ｂおよび５−ｈｔ２ｃ受容体リガンドとしてのそれらの使用
TW201109327A (en) Heterocyclic compound
KR100618748B1 (ko) 피페라진 유도체
EP1109809A1 (en) Pyrroloquinolines for treatment of obesity
CN111116572B (zh) 噁二唑衍生物及其制备方法和用途
HK1034967B (en) Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
HK1034967A1 (en) Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists

Legal Events

Date Code Title Description
R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20091003

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20091003

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000